Epidermolysis Bullosa
Group of genetically determined disorders characterized by the blistering of skin and mucosae. There are four major forms: acquired, simple, junctional, and dystrophic. Each of the latter three has several varieties.
Subtype terms (4)
More specific conditions that are subtypes of Epidermolysis Bullosa in the MeSH hierarchy.
- Epidermolysis Bullosa Acquisita
2 drugs approved
- Epidermolysis Bullosa Dystrophica
23 drugs (6 approved, 17 experimental)
- Epidermolysis Bullosa, Junctional
6 drugs (2 approved, 4 experimental)
- Epidermolysis Bullosa Simplex
9 drugs (6 approved, 3 experimental)
Drugs by status
Approved for this indication (3)
Phase 4 trials (3)
Phase 3 trials (9)
Phase 2 trials (26)
- tacrolimus
- bone marrow derived mesenchymal stem cells
- serlopitant
- cyclosporine
- mycophenolate
- cyclophosphamide
- thymosin beta-4
- Anti-thymocyte Globulin (Rabbit)
- allogeneic adipose derived mesenchymal stem cell
- umbilical cord mesenchymal stem cells
- cx501
- genetically corrected cultured epidermal autograft
- lzrse-col7a1 engineered autologous epidermal sheets
- allogeneic bone marrow
- autologous mesenchymal stem cells
- gentamicin
- fludarabine
- cord blood stem cells
- Allantoin
- eugenol
- trimethoprim
- diacerein
- efgartigimod
- allo-apz2-eb
- human collagen 7
- tcp-25
Phase 1 trials (10)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (16)
- Abeona Therapeutics
- Shire
- Amicus Therapeutics
- Amryt Research Limited
- Fibrocell Technologies, Inc.
- Scioderm, Inc.
- The Hospital for Sick Children
- Melbourne Health
- Stanford University
- University of Toronto
- Castle Creek Pharmaceuticals
- University of Toulouse
- H&E Enterprises
- University of Nice Sophia Antipolis
- Krystal Biotech, Inc.
- Avicanna Inc
Organization Involved with Phase 2 Indications (37)
- Intrexon
- Aeglea Biotherapeutics
- Cellerix
- FGK Clinical Research GmbH
- Holostem Terapie Avanzate s.r.l.
- Vyne Therapeutics Inc.
- ProQR Therapeutics
- RegeneRx Biopharmaceuticals, Inc.
- Rheacell GmbH & Co. KG
- Daewoong Pharmaceutical Co. LTD.
- Healthpoint
- TWi Biotechnology, Inc.
- National Center for Research Resources (NCRR)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- University of London
- Northwestern University
- Paracelsus Medical University
- Universidad Autonoma de Madrid
- University of Oslo
- University of Salzburg
- University of Southern California
- Yonsei University
- Premier Specialists, Australia
- Tel Aviv University
- Uppsala University
- Vanderbilt University
- University of Minnesota
- Ichilov Medical Center
- University of New South Wales
- CIBERER
- +7 more
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (1)